Abstract
The purine nucleoside analog (PNA) - cladribine (2-CdA, 2-chlorodeoxyadenosine) is a cytotoxic agent of high efficacy in lymphoid and myeloid malignancies. This drug was approved by the FDA for treatment of hairy cell leukemia and in some European countries for treatment of refractory/relapsed chronic lymphocytic leukemia. 2-CdA is usually administered as continuous or intermittent intravenous infusion. Recently however, new formulations of this agent has been developed for subcutaneous and oral administration. In contrast to other PNA, 2-CdA is equally cytotoxic to both proliferating and quiescent cells and several pathways may be responsible for the mechanism of its action. In addition, recent data indicate that 2-CdA combined with other cytotoxic agents and monoclonal antibodies show synergistic proapoptotic and cytotoxic activity on lymphoid and myeloid neoplastic cells. This review article summarizes recent achievements in the understanding of 2-CdA mechanism of action, pharmacokinetics of different pharmaceutical formulations and its approved and possible future applications in the treatment of hematological malignancies. The most important recent patents concerning oral formulations of 2-CdA have been presented.
Keywords: Cladribine, oral, subcutaneous, pharmacokinetics, leukemia, lymphoma, systemic mastocytosis, Langerhans cell histiocytosis, acute myeloid leukemia
Recent Patents on Anti-Cancer Drug Discovery
Title: Older and New Formulations of Cladribine. Pharmacology and Clinical Efficacy in Hematological Malignancies
Volume: 1 Issue: 1
Author(s): Tadeusz Robak, Anna Korycka and Ewa Robak
Affiliation:
Keywords: Cladribine, oral, subcutaneous, pharmacokinetics, leukemia, lymphoma, systemic mastocytosis, Langerhans cell histiocytosis, acute myeloid leukemia
Abstract: The purine nucleoside analog (PNA) - cladribine (2-CdA, 2-chlorodeoxyadenosine) is a cytotoxic agent of high efficacy in lymphoid and myeloid malignancies. This drug was approved by the FDA for treatment of hairy cell leukemia and in some European countries for treatment of refractory/relapsed chronic lymphocytic leukemia. 2-CdA is usually administered as continuous or intermittent intravenous infusion. Recently however, new formulations of this agent has been developed for subcutaneous and oral administration. In contrast to other PNA, 2-CdA is equally cytotoxic to both proliferating and quiescent cells and several pathways may be responsible for the mechanism of its action. In addition, recent data indicate that 2-CdA combined with other cytotoxic agents and monoclonal antibodies show synergistic proapoptotic and cytotoxic activity on lymphoid and myeloid neoplastic cells. This review article summarizes recent achievements in the understanding of 2-CdA mechanism of action, pharmacokinetics of different pharmaceutical formulations and its approved and possible future applications in the treatment of hematological malignancies. The most important recent patents concerning oral formulations of 2-CdA have been presented.
Export Options
About this article
Cite this article as:
Robak Tadeusz, Korycka Anna and Robak Ewa, Older and New Formulations of Cladribine. Pharmacology and Clinical Efficacy in Hematological Malignancies, Recent Patents on Anti-Cancer Drug Discovery 2006; 1 (1) . https://dx.doi.org/10.2174/157489206775246467
DOI https://dx.doi.org/10.2174/157489206775246467 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Noscapine and its Analogs as Chemotherapeutic Agent: Current updates
Current Topics in Medicinal Chemistry The Role of Pemetrexed in Advanced Non Small-Cell Lung Cancer: Special Focus on Pharmacology and Mechanism of Action
Current Drug Targets Sphingosine Analogs and Protein Phosphatase 2A as a Molecular Targeted Cancer Therapy: A Mini Systematic Review
Clinical Cancer Drugs Histone Deacetylases: Anti-Angiogenic Targets in Cancer Therapy
Current Cancer Drug Targets Current Constructs and Targets in Clinical Development for Antibody- Based Cancer Therapy
Current Drug Targets Radiation Therapy in the Early 21st Century: Technological Advances
Current Cancer Therapy Reviews Schizophrenia: A Systematic Review of the Disease State, Current Therapeutics and their Molecular Mechanisms of Action
Current Medicinal Chemistry New Use for Old Drugs? Prospective Targets of Chloroquines in Cancer Therapy
Current Drug Targets Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets Tumor Angiogenesis: A Target for Renal Cell Carcinoma Therapy. Current Perspectives and Novel Strategies
Recent Patents on Biomarkers Bone Marrow Mesenchymal Stem Cells: Agents of Immunomodulation and Neuroprotection
Current Stem Cell Research & Therapy PRAME/EZH2-Mediated Regulation of TRAIL: A New Target for Cancer Therapy
Current Molecular Medicine Prospective Evaluation of the Dosing Regimen of Vancomycin in Children of Different Weight Categories
Current Drug Safety Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments
Current Medicinal Chemistry Potential Utilization of Bystander / Abscopal-Mediated Signal Transduction Events in the Treatment of Solid Tumors
Current Signal Transduction Therapy Editorial (Thematic Issue: Immunophilins, Protein Chemistry and Cell Biology of a Promising New Class of Drug Targets – Part II)
Current Molecular Pharmacology Biomarkers Associated with Bleeding Risk in the Setting of Atrial Fibrillation
Current Medicinal Chemistry Recombinant Human Insulin-Like Growth Factor-1: A New Cardiovascular Disease Treatment Option?
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeting Trail Towards the Clinic
Current Drug Targets Posterior Reversible Encephalopathy Syndrome in Leukemic Children: A Sensitive Issue
Current Drug Safety